- Home
- SWTX vs ACAD Comparison
SWTX vs ACAD Comparison
Compare SWTX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- ACAD
- Stock Information
- Founded
- SWTX 2017
- ACAD 1993
- Country
- SWTX United States
- ACAD United States
- Employees
- SWTX N/A
- ACAD N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SWTX Health Care
- ACAD Health Care
- Exchange
- SWTX Nasdaq
- ACAD Nasdaq
- Market Cap
- SWTX 3.0B
- ACAD 2.8B
- IPO Year
- SWTX 2019
- ACAD 2004
- Fundamental
- Price
- SWTX $37.92
- ACAD $14.73
- Analyst Decision
- SWTX Strong Buy
- ACAD Buy
- Analyst Count
- SWTX 5
- ACAD 16
- Target Price
- SWTX $72.40
- ACAD $23.93
- AVG Volume (30 Days)
- SWTX 2.2M
- ACAD 1.8M
- Earning Date
- SWTX 05-01-2025
- ACAD 05-07-2025
- Dividend Yield
- SWTX N/A
- ACAD N/A
- EPS Growth
- SWTX N/A
- ACAD N/A
- EPS
- SWTX N/A
- ACAD 1.36
- Revenue
- SWTX $191,589,000.00
- ACAD $957,797,000.00
- Revenue This Year
- SWTX $85.98
- ACAD $13.07
- Revenue Next Year
- SWTX $69.16
- ACAD $9.88
- P/E Ratio
- SWTX N/A
- ACAD $10.83
- Revenue Growth
- SWTX 3417.33
- ACAD 31.85
- 52 Week Low
- SWTX $28.21
- ACAD $13.40
- 52 Week High
- SWTX $62.00
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- SWTX 39.33
- ACAD 38.07
- Support Level
- SWTX $36.08
- ACAD $14.34
- Resistance Level
- SWTX $38.77
- ACAD $15.18
- Average True Range (ATR)
- SWTX 3.21
- ACAD 0.80
- MACD
- SWTX -0.17
- ACAD -0.02
- Stochastic Oscillator
- SWTX 36.05
- ACAD 38.22
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.